Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice

Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Five-week-o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2010-09, Vol.16 (18), p.4595-4606
Hauptverfasser: RAVICHANDRAN, Kameswaran, VELMURUGAN, Balaiya, GU, Mallikarjuna, SINGH, Rana P, AGARWAL, Rajesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4606
container_issue 18
container_start_page 4595
container_title Clinical cancer research
container_volume 16
creator RAVICHANDRAN, Kameswaran
VELMURUGAN, Balaiya
GU, Mallikarjuna
SINGH, Rana P
AGARWAL, Rajesh
description Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis. Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P < 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P < 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P < 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin. Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention.
doi_str_mv 10.1158/1078-0432.ccr-10-1213
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3000041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20823143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</originalsourceid><addsrcrecordid>eNpVkM1OGzEUhS1UBBR4BCpvWE7iO7bHkw1SNII2CITEz4qF5fHYiauJjexJ1fD0dYAEeje-Oj7nXOlD6AzICIDXYyCiLgij5UjrWAApoAS6h46Ac1HQsuLf8r71HKLvKf0mBBgQdoAOS1KXFBg9Qs8zv3CtG0Jc40trjR5wsPjB9Vn0zmM1V86nAU9fw9_10gwL5U0x891Kmw43oQ8eP66WIbq58Sa5hHNmOr7Gt06bE7RvVZ_M6cd7jJ6uLh-bX8XN3c9ZM70pNOf1UAg6EYy2olVWmEpVRFSEdrZsOenERAPXhpUVCG5aOxEKsspYR0Rbt1bTWtBjdPHe-7Jql6bTxg9R9fIluqWKaxmUk___eLeQ8_BHUpKHQS7g7wU6hpSisbssELmhLTck5YakbJr7NzXTzrkfXw_vUlu82XD-YVBJq95G5bVLnz5aMiEqoP8AyhiJtQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>RAVICHANDRAN, Kameswaran ; VELMURUGAN, Balaiya ; GU, Mallikarjuna ; SINGH, Rana P ; AGARWAL, Rajesh</creator><creatorcontrib>RAVICHANDRAN, Kameswaran ; VELMURUGAN, Balaiya ; GU, Mallikarjuna ; SINGH, Rana P ; AGARWAL, Rajesh</creatorcontrib><description>Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis. Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P &lt; 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P &lt; 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P &lt; 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin. Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.ccr-10-1213</identifier><identifier>PMID: 20823143</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Angiogenic Proteins - metabolism ; Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Apoptosis - drug effects ; Azoxymethane ; Biological and medical sciences ; Carcinogens ; Carcinoma - chemically induced ; Carcinoma - pathology ; Carcinoma - prevention &amp; control ; Cell Proliferation - drug effects ; Colonic Neoplasms - chemically induced ; Colonic Neoplasms - pathology ; Colonic Neoplasms - prevention &amp; control ; Cytoprotection - drug effects ; Dose-Response Relationship, Drug ; Down-Regulation - drug effects ; Drug Evaluation, Preclinical ; Inflammation Mediators - metabolism ; Male ; Medical sciences ; Mice ; Mice, Inbred Strains ; Pharmacology. Drug treatments ; Silymarin - pharmacology ; Silymarin - therapeutic use</subject><ispartof>Clinical cancer research, 2010-09, Vol.16 (18), p.4595-4606</ispartof><rights>2015 INIST-CNRS</rights><rights>2010 AACR.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</citedby><cites>FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23247761$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20823143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RAVICHANDRAN, Kameswaran</creatorcontrib><creatorcontrib>VELMURUGAN, Balaiya</creatorcontrib><creatorcontrib>GU, Mallikarjuna</creatorcontrib><creatorcontrib>SINGH, Rana P</creatorcontrib><creatorcontrib>AGARWAL, Rajesh</creatorcontrib><title>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis. Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P &lt; 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P &lt; 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P &lt; 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin. Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention.</description><subject>Angiogenic Proteins - metabolism</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Azoxymethane</subject><subject>Biological and medical sciences</subject><subject>Carcinogens</subject><subject>Carcinoma - chemically induced</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - prevention &amp; control</subject><subject>Cell Proliferation - drug effects</subject><subject>Colonic Neoplasms - chemically induced</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - prevention &amp; control</subject><subject>Cytoprotection - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Down-Regulation - drug effects</subject><subject>Drug Evaluation, Preclinical</subject><subject>Inflammation Mediators - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Pharmacology. Drug treatments</subject><subject>Silymarin - pharmacology</subject><subject>Silymarin - therapeutic use</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkM1OGzEUhS1UBBR4BCpvWE7iO7bHkw1SNII2CITEz4qF5fHYiauJjexJ1fD0dYAEeje-Oj7nXOlD6AzICIDXYyCiLgij5UjrWAApoAS6h46Ac1HQsuLf8r71HKLvKf0mBBgQdoAOS1KXFBg9Qs8zv3CtG0Jc40trjR5wsPjB9Vn0zmM1V86nAU9fw9_10gwL5U0x891Kmw43oQ8eP66WIbq58Sa5hHNmOr7Gt06bE7RvVZ_M6cd7jJ6uLh-bX8XN3c9ZM70pNOf1UAg6EYy2olVWmEpVRFSEdrZsOenERAPXhpUVCG5aOxEKsspYR0Rbt1bTWtBjdPHe-7Jql6bTxg9R9fIluqWKaxmUk___eLeQ8_BHUpKHQS7g7wU6hpSisbssELmhLTck5YakbJr7NzXTzrkfXw_vUlu82XD-YVBJq95G5bVLnz5aMiEqoP8AyhiJtQ</recordid><startdate>20100915</startdate><enddate>20100915</enddate><creator>RAVICHANDRAN, Kameswaran</creator><creator>VELMURUGAN, Balaiya</creator><creator>GU, Mallikarjuna</creator><creator>SINGH, Rana P</creator><creator>AGARWAL, Rajesh</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20100915</creationdate><title>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</title><author>RAVICHANDRAN, Kameswaran ; VELMURUGAN, Balaiya ; GU, Mallikarjuna ; SINGH, Rana P ; AGARWAL, Rajesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Angiogenic Proteins - metabolism</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Azoxymethane</topic><topic>Biological and medical sciences</topic><topic>Carcinogens</topic><topic>Carcinoma - chemically induced</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - prevention &amp; control</topic><topic>Cell Proliferation - drug effects</topic><topic>Colonic Neoplasms - chemically induced</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - prevention &amp; control</topic><topic>Cytoprotection - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Down-Regulation - drug effects</topic><topic>Drug Evaluation, Preclinical</topic><topic>Inflammation Mediators - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Pharmacology. Drug treatments</topic><topic>Silymarin - pharmacology</topic><topic>Silymarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RAVICHANDRAN, Kameswaran</creatorcontrib><creatorcontrib>VELMURUGAN, Balaiya</creatorcontrib><creatorcontrib>GU, Mallikarjuna</creatorcontrib><creatorcontrib>SINGH, Rana P</creatorcontrib><creatorcontrib>AGARWAL, Rajesh</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RAVICHANDRAN, Kameswaran</au><au>VELMURUGAN, Balaiya</au><au>GU, Mallikarjuna</au><au>SINGH, Rana P</au><au>AGARWAL, Rajesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2010-09-15</date><risdate>2010</risdate><volume>16</volume><issue>18</issue><spage>4595</spage><epage>4606</epage><pages>4595-4606</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis. Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P &lt; 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P &lt; 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P &lt; 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin. Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>20823143</pmid><doi>10.1158/1078-0432.ccr-10-1213</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2010-09, Vol.16 (18), p.4595-4606
issn 1078-0432
1557-3265
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3000041
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Angiogenic Proteins - metabolism
Animals
Antineoplastic agents
Antineoplastic Agents - pharmacology
Antioxidants - pharmacology
Antioxidants - therapeutic use
Apoptosis - drug effects
Azoxymethane
Biological and medical sciences
Carcinogens
Carcinoma - chemically induced
Carcinoma - pathology
Carcinoma - prevention & control
Cell Proliferation - drug effects
Colonic Neoplasms - chemically induced
Colonic Neoplasms - pathology
Colonic Neoplasms - prevention & control
Cytoprotection - drug effects
Dose-Response Relationship, Drug
Down-Regulation - drug effects
Drug Evaluation, Preclinical
Inflammation Mediators - metabolism
Male
Medical sciences
Mice
Mice, Inbred Strains
Pharmacology. Drug treatments
Silymarin - pharmacology
Silymarin - therapeutic use
title Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A57%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibitory%20Effect%20of%20Silibinin%20against%20Azoxymethane-Induced%20Colon%20Tumorigenesis%20in%20A/J%20Mice&rft.jtitle=Clinical%20cancer%20research&rft.au=RAVICHANDRAN,%20Kameswaran&rft.date=2010-09-15&rft.volume=16&rft.issue=18&rft.spage=4595&rft.epage=4606&rft.pages=4595-4606&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.ccr-10-1213&rft_dat=%3Cpubmed_cross%3E20823143%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20823143&rfr_iscdi=true